Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
(CSE:
MBIO
)
0.1250
UNCHANGED
Delayed Quote
Updated: 12:28 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MBIO
< Previous
1
2
3
Next >
MindBio Therapeutics Team Members Honoured with Industry Leading Awards
November 21, 2023
Via
ACCESSWIRE
MindBio Therapeutics CEO Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer Patients
October 31, 2023
Via
ACCESSWIRE
MindBio Therapeutics Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial In Advanced Stage Cancer Patients
October 28, 2023
Via
ACCESSWIRE
Mindbio Therapeutics Nominated for Company of the Year in Industry Awards
October 26, 2023
Via
ACCESSWIRE
MindBio Therapeutics CEO Provides Video Update on Phase 2a Depression Trial Using MB22001
October 24, 2023
Via
ACCESSWIRE
Tenth Patient With Depression Starts Dosing MB22001 in Take Home Microdosing Trials
October 05, 2023
Via
ACCESSWIRE
Mindbio Therapeutics CEO Provides Update on Depression Trial & Novel Discoveries in Psychedelics Research
September 14, 2023
Via
ACCESSWIRE
MindBio Therapeutics Announces Major Genetic Discovery in Microdosing Research
September 05, 2023
Via
ACCESSWIRE
Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression
August 24, 2023
Via
ACCESSWIRE
Mindbio Therapeutics First Batch of MB22001 has Been Manufactured and is Ready for Use in World First Phase 2 Take at Home Psychedelic Clinical Trials
August 18, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
